SUMMARY In 15 patients with Alzheimer's disease and in 10 with Down's syndrome at middle age, there was severe atrophy, neurofibrillary degeneration and loss of pigmented dopaminergic nerve cells from ventral tegmental area (A10) whereas nerve cells in neighbouring substantia nigra (A9) were much less affected in all three respects. It is suggested that these findings may represent different patterns of damage within the two systems in these conditions which may relate to the presence of Alzheimer type changes (senile plaques) within their respective projection fields.
While an atrophy, neurofibrillary degeneration and loss of those nerve cells comprising the cortically projecting cholinergic,1 15 noradrenergic"' 14 Dopaminergic neurotransmitter systems in Alzheimer's disease and in Down's syndrome at middle age d). These changes were often more severe in Alzheimer's disease patients under 75 years of age.
Cell counting (table) showed that when compared with age-matched control patients, the number of surviving cells in SN was slightly lower (15-17%) (p < 0-05) in Alzheimer's disease, but not significantly lower in Down's syndrome. The number of surviving cells in VTA, however, was significantly lower (40-60%) (p < 0-01 at least) in both patient groups (table). Nucleolar volume was reduced in cells of SN, in both groups, by 18-30%, whereas that in cells of VTA was decreased (p < 0-001) by more than 35% in both groups. No significant differences in either cell number or nucleolar volume were noted in either SN or VTA between the Down's syndrome and the six youngest Alzheimer's disease patients (which matched the Down's syndrome group for age) (table).
Discussion
Findings that the dopaminergic cells of the VTA (A10) are severely affected in Alzheimer's disease and Down's syndrome at middle age, whereas those of SN (A9) are much less damaged, has important pathogenetic implications. Neurons of VTA project to frontal and limbic areas of cortex whereas those of SN project to basal ganglia. It is difficult to conceive of a pathogenic event acting directly on dopaminergic cell bodies that would severely affect those of VTA, while sparing (relatively) those of SN. What seems more likely is that the primary damage to these neurons occurs within their terminal fields, with reduction in nucleolar volume (atrophy), neurofibrillary degeneration and loss of perikarya following as secondary retrograde changes. The observations that the pathological hallmarks of Alzheimer's disease (that is, plaques and tangles) are numerous in frontal and limbic areas, but scarce in basal ganglia, would be consistent with this argument.
There is evidence from other transmitter systems to support the concept that the subcortical damage of Alzheimer's disease and Down's syndrome is secondary to primary changes within cerebral cortex. For example, Perry and colleagues2 have shown that loss of cortical cholineacetyltransferase activity (CAT) far exceeds nerve cell loss within the parent nucleus basalis; indeed Pearson et VTA may also be damaged in a similar way to those of nucleus basalis and locus caeruleus. The much lesser degree of neurofibrillary degeneration, atrophy and loss of cells in SN, may relate either to the few plaques within basal ganglia, or it may arise from some degree of collateralisation (either "intended" or "aberrant") with the cerebral cortex.
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